Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer
Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer
复制标题
DOI：
10.1007/s12032-014-0058-9
复制
发表时间：
2014-07-01
期刊：
影响因子：
3.4
通讯作者：
Elity, Mohamed Mosad
中科院分区：
文献类型：
--
作者：
Sad, Lamiss Mohamed;Younis, Samar Galal;Elity, Mohamed Mosad
全身治疗可提高晚期非小细胞肺癌（NSCLC）患者的生存率和生活质量。晚期NSCLC出现了几种新的治疗选择，包括新型细胞毒性药物（紫杉烷类、吉西他滨、培美曲塞）和分子靶向药物（厄洛替尼、贝伐珠单抗），生存期的最佳预后标志物仍不清楚。本研究的目的是评估临床病理特征和切除修复交叉互补组-1（ERCC 1）在接受顺铂为基础的化疗的局部晚期NSCLC患者中的预后价值。收集了80例经组织病理学证实的非小细胞肺癌患者的临床资料，这些患者计划接受以顺铂为基础的辅助化疗。免疫组化检测80例患者ERCC 1蛋白表达水平。观察ERCC 1蛋白表达水平与患者临床结局的关系。III期NSCLC化疗加同步放化疗的3年生存率为20%，中位生存时间为10个月。ERCC 1阴性肿瘤患者的生存期明显长于ERCC 1阳性肿瘤患者（p = 0.0001）。与总生存率相关的预后因素为体能状态、吸烟、分期、体重减轻和ERCC 1。无进展生存期的预后因素为分期、体重减轻、ERCC 1和ERCC 1进展阳性程度。ERCC 1蛋白表达可能在局部晚期NSCLC患者接受以顺铂为基础的辅助化疗后的预后中起重要作用。
Systemic therapy improves the survival and quality of life of patients with advanced stage non-small cell lung cancer (NSCLC). Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. Clinical data concerning 80 patients with histopathologically confirmed non-small cell lung cancer who are planned to receive cisplatin-based adjuvant chemotherapy were collected. The protein expression levels for ERCC1 are immunohistochemical examined in 80 patients. The relationship between the ERCC1 protein expression level and the clinical outcomes of the patients is then observed. The 3-year survival rate and median survival time of stage III NSCLC received chemotherapy with/without concurrent chemoradiotherapy were 20 % and 10 months, respectively. Survival of patients with ERCC1-negative tumors was significantly longer than those with ERCC1-positive tumors (p = 0.0001). Prognostic factors with overall survival were performance status, cigarette smoking, stage, weight loss and ERCC1. While as regard progression-free survival prognostic factors were stage, weight loss, ERCC1 and degree of positivity of ERCC1 progression. It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy.